Equity Profile

ERAS

Erasca, Inc.

Health CareBiotechnology$6.2B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for innovative therapies grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1 2026, Erasca reported an EPS of -$0.60, which was significantly below the expected -$0.19. The stock reacted positively, increasing by 3.16% the following day despite the miss.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to managing costs effectively.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Erasca's upcoming earnings report, especially after a disappointing EPS last quarter. The market is looking for signs of improved financial performance and updates on drug development.

Bull Case

If Erasca can show a smaller loss than expected and provide positive updates on its drug pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports a larger loss and lacks clarity on its future prospects, it may lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

Investors will closely watch for any delays or advancements, as these can significantly impact future revenue potential.

How is the company managing its R&D budget in light of recent losses?

Effective management of R&D spending will be critical for sustaining growth and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Erasca's drug pipeline to yield positive results, despite recent setbacks.

Supporting Evidence

The company has a history of surprising investors with better-than-expected trial results.

Options pricing indicates a significant move, suggesting that traders are anticipating volatility that could favor the upside.

Key Risk

If clinical trial updates are more positive than expected, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to manage costs while advancing its drug pipeline.

Bull Confirmed If

A smaller loss than -$0.60 and positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

A larger loss than expected and lack of clarity on drug development would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could see a modest increase of around 1.65% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 7.79%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key clinical trials.
2Details on cost management strategies.
3Any new partnerships or collaborations announced.
4Insights into the competitive landscape for Erasca's drug candidates.
5Management's outlook on future revenue growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1 2026, Erasca reported an EPS of -$0.60, which was significantly below the expected -$0.19. The stock reacted positively, increasing by 3.16% the following day despite the miss.

Management Promises & Guidance

Focus on advancing clinical trials for key drug candidates.
Commitment to managing costs effectively.
Plans to enhance partnerships for drug development.

Expectations

Wall Street Expectations

Bull Case

If Erasca can show a smaller loss than expected and provide positive updates on its drug pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports a larger loss and lacks clarity on its future prospects, it may lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key clinical trials?

Investors will closely watch for any delays or advancements, as these can significantly impact future revenue potential.

How is the company managing its R&D budget in light of recent losses?

Effective management of R&D spending will be critical for sustaining growth and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Erasca's drug pipeline to yield positive results, despite recent setbacks.

Supporting Evidence

The company has a history of surprising investors with better-than-expected trial results.

Options pricing indicates a significant move, suggesting that traders are anticipating volatility that could favor the upside.

Key Risk

If clinical trial updates are more positive than expected, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to manage costs while advancing its drug pipeline.

Bull Confirmed If

A smaller loss than -$0.60 and positive updates on clinical trials would confirm the bull case.

Bear Confirmed If

A larger loss than expected and lack of clarity on drug development would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±42.1% while ERAS has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could see a modest increase of around 1.65% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 7.79%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key clinical trials.
2Details on cost management strategies.
3Any new partnerships or collaborations announced.
4Insights into the competitive landscape for Erasca's drug candidates.
5Management's outlook on future revenue growth.